블로그

• A phase 1b/2, open-label study of adrixetinib (Q702) in combination with intravenous pembrolizumab The safety profile, pharmacokinetics (PK) and efficacy data for Q702 in combination with pembrolizumab advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers who have progressed on prior anti-PD blog.naver.com · 2025.06.03